BMS' teniposide
Executive Summary
Will be reviewed by FDA's Oncologic Drugs Advisory Committee at its July 1-2 meeting at FDA's Parklawn Building in conference rooms D & E. Teniposide's NDA for treatment of refractory childhood acute lymphocytic leukemia was filed in September 1990. Teniposide was approved as a Treatment IND/Group C drug in October 1988 for use in combination with the cancer drug cytarabine to treat refractory lymphoblastic leukemia. Teniposide was licensed from Sandoz, and is marketed worldwide by BMS, except in French territories, under the tradename Vumon.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth